secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001213900-24-021461
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx reaffirms FY2023 prelim revenue >$68-70M; updates 2024 revenue guidance to at least $100M
--------------------------------------------------------------------------------

- FY2023 preliminary revenue exceeds $68-70M range; adjusted EBITDA in $3-4M range, consistent with prior guidance.
- 2024 revenue guidance revised to at least $100M due to gross-to-net revenue recognition change for Medicx Health.
- 2024 adjusted EBITDA guidance unchanged at greater than $11M.
- FY2023 earnings call scheduled for March 28, 2024; year-end audit ongoing including Medicx Health and material weakness remediation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/0001213900-24-021461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390024021461/ea0201581-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-021461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer